Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats

Éva Matucz, Krisztina Móricz, Gábor Gigler, Angéla Benedek, József Barkóczy, György Lévay, L. Hársing, G. Szénási

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid) antagonists that effectively protected against tissue injury caused by global and focal cerebral ischemia in laboratory animals. This study evaluated the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 in permanent and transient middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. Infarct size was measured by TTC staining 48 h after permanent MCAO (electrocoagulation), and 24 h after reperfusion following a 1-h transient MCAO carried out using the intraluminal filament technique. Treatment with EGIS-8332 (10 mg/kg, i.p.) 60 or 120 min after permanent MCAO, decreased infarct size by 30% and 36%, respectively, and the effect of GYKI 53405 (10 mg/kg, i.p.) was similar (30% and 33%, respectively; p <0.01 all). Neither compound was effective if administered 180 or 240 min after permanent MCAO. Both EGIS-8332 and GYKI 53405 (20 mg/kg, i.p.) reduced the core and total (core plus penumbra) volumes of tissue injury in the whole brain and the cerebral cortex when administered 120 or 180 min after transient MCAO. The compounds did not alter tissue damage in the striatum. No neuroprotective effect was obtained at 240 min after transient MCAO. In conclusion, the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 was 2 h in permanent and 3 h in transient focal cerebral ischemia in rats. The results suggest that treatment with non-competitive AMPA antagonists can only be expected to produce a neuroprotective action in humans if administered shortly after the appearance of stroke symptoms.

Original languageEnglish
Pages (from-to)60-67
Number of pages8
JournalBrain Research
Volume1123
Issue number1
DOIs
Publication statusPublished - Dec 6 2006

Fingerprint

GYKI 53405
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Middle Cerebral Artery Infarction
Brain Ischemia
Therapeutics
Electrocoagulation
Transient Ischemic Attack
Wounds and Injuries
Laboratory Animals
Neuroprotective Agents
Neuroprotection
Cerebral Cortex
Reperfusion
Sprague Dawley Rats
Stroke
EGIS-8332
Staining and Labeling
Brain

Keywords

  • AMPA antagonist
  • Middle cerebral artery occlusion
  • Neuroprotection
  • Therapeutic time window

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. / Matucz, Éva; Móricz, Krisztina; Gigler, Gábor; Benedek, Angéla; Barkóczy, József; Lévay, György; Hársing, L.; Szénási, G.

In: Brain Research, Vol. 1123, No. 1, 06.12.2006, p. 60-67.

Research output: Contribution to journalArticle

Matucz, Éva ; Móricz, Krisztina ; Gigler, Gábor ; Benedek, Angéla ; Barkóczy, József ; Lévay, György ; Hársing, L. ; Szénási, G. / Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. In: Brain Research. 2006 ; Vol. 1123, No. 1. pp. 60-67.
@article{1dd525d35b7148c2b45579412748e68c,
title = "Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats",
abstract = "EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid) antagonists that effectively protected against tissue injury caused by global and focal cerebral ischemia in laboratory animals. This study evaluated the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 in permanent and transient middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. Infarct size was measured by TTC staining 48 h after permanent MCAO (electrocoagulation), and 24 h after reperfusion following a 1-h transient MCAO carried out using the intraluminal filament technique. Treatment with EGIS-8332 (10 mg/kg, i.p.) 60 or 120 min after permanent MCAO, decreased infarct size by 30{\%} and 36{\%}, respectively, and the effect of GYKI 53405 (10 mg/kg, i.p.) was similar (30{\%} and 33{\%}, respectively; p <0.01 all). Neither compound was effective if administered 180 or 240 min after permanent MCAO. Both EGIS-8332 and GYKI 53405 (20 mg/kg, i.p.) reduced the core and total (core plus penumbra) volumes of tissue injury in the whole brain and the cerebral cortex when administered 120 or 180 min after transient MCAO. The compounds did not alter tissue damage in the striatum. No neuroprotective effect was obtained at 240 min after transient MCAO. In conclusion, the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 was 2 h in permanent and 3 h in transient focal cerebral ischemia in rats. The results suggest that treatment with non-competitive AMPA antagonists can only be expected to produce a neuroprotective action in humans if administered shortly after the appearance of stroke symptoms.",
keywords = "AMPA antagonist, Middle cerebral artery occlusion, Neuroprotection, Therapeutic time window",
author = "{\'E}va Matucz and Krisztina M{\'o}ricz and G{\'a}bor Gigler and Ang{\'e}la Benedek and J{\'o}zsef Bark{\'o}czy and Gy{\"o}rgy L{\'e}vay and L. H{\'a}rsing and G. Sz{\'e}n{\'a}si",
year = "2006",
month = "12",
day = "6",
doi = "10.1016/j.brainres.2006.09.043",
language = "English",
volume = "1123",
pages = "60--67",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats

AU - Matucz, Éva

AU - Móricz, Krisztina

AU - Gigler, Gábor

AU - Benedek, Angéla

AU - Barkóczy, József

AU - Lévay, György

AU - Hársing, L.

AU - Szénási, G.

PY - 2006/12/6

Y1 - 2006/12/6

N2 - EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid) antagonists that effectively protected against tissue injury caused by global and focal cerebral ischemia in laboratory animals. This study evaluated the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 in permanent and transient middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. Infarct size was measured by TTC staining 48 h after permanent MCAO (electrocoagulation), and 24 h after reperfusion following a 1-h transient MCAO carried out using the intraluminal filament technique. Treatment with EGIS-8332 (10 mg/kg, i.p.) 60 or 120 min after permanent MCAO, decreased infarct size by 30% and 36%, respectively, and the effect of GYKI 53405 (10 mg/kg, i.p.) was similar (30% and 33%, respectively; p <0.01 all). Neither compound was effective if administered 180 or 240 min after permanent MCAO. Both EGIS-8332 and GYKI 53405 (20 mg/kg, i.p.) reduced the core and total (core plus penumbra) volumes of tissue injury in the whole brain and the cerebral cortex when administered 120 or 180 min after transient MCAO. The compounds did not alter tissue damage in the striatum. No neuroprotective effect was obtained at 240 min after transient MCAO. In conclusion, the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 was 2 h in permanent and 3 h in transient focal cerebral ischemia in rats. The results suggest that treatment with non-competitive AMPA antagonists can only be expected to produce a neuroprotective action in humans if administered shortly after the appearance of stroke symptoms.

AB - EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid) antagonists that effectively protected against tissue injury caused by global and focal cerebral ischemia in laboratory animals. This study evaluated the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 in permanent and transient middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. Infarct size was measured by TTC staining 48 h after permanent MCAO (electrocoagulation), and 24 h after reperfusion following a 1-h transient MCAO carried out using the intraluminal filament technique. Treatment with EGIS-8332 (10 mg/kg, i.p.) 60 or 120 min after permanent MCAO, decreased infarct size by 30% and 36%, respectively, and the effect of GYKI 53405 (10 mg/kg, i.p.) was similar (30% and 33%, respectively; p <0.01 all). Neither compound was effective if administered 180 or 240 min after permanent MCAO. Both EGIS-8332 and GYKI 53405 (20 mg/kg, i.p.) reduced the core and total (core plus penumbra) volumes of tissue injury in the whole brain and the cerebral cortex when administered 120 or 180 min after transient MCAO. The compounds did not alter tissue damage in the striatum. No neuroprotective effect was obtained at 240 min after transient MCAO. In conclusion, the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 was 2 h in permanent and 3 h in transient focal cerebral ischemia in rats. The results suggest that treatment with non-competitive AMPA antagonists can only be expected to produce a neuroprotective action in humans if administered shortly after the appearance of stroke symptoms.

KW - AMPA antagonist

KW - Middle cerebral artery occlusion

KW - Neuroprotection

KW - Therapeutic time window

UR - http://www.scopus.com/inward/record.url?scp=33751190756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751190756&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2006.09.043

DO - 10.1016/j.brainres.2006.09.043

M3 - Article

C2 - 17064671

AN - SCOPUS:33751190756

VL - 1123

SP - 60

EP - 67

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -